Адъювантная гормонотерапия женщин в перименопаузе с РЭ-положительным раком молочной железы
- Авторы: Семиглазов В.Ф1, Семиглазов В.В2
-
Учреждения:
- НИИ онкологии им. Н.Н. Петрова
- СПбГМУ им. акад. И.П. Павлова
- Выпуск: № 18 (2012)
- Страницы: 71-75
- Раздел: Статьи
- URL: https://journals.eco-vector.com/2073-4034/article/view/280009
- ID: 280009
Цитировать
Полный текст
![Открытый доступ](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_open.png)
![Доступ закрыт](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_unlock.png)
![Доступ закрыт](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
Аннотация
Для больных гормоночувствительным первичным раком молочной железы, имеющих клинические или биохимические признаки синтеза овариальных эстрогенов, применение ингибиторов ароматазы противопоказано. Измерение уровней эстрадиола и фолликулостимулирующего гормона должно быть проведено до и во время лечения ингибиторами ароматазы женщинам, не являющимся явно постменопаузальными или имеющими риск возобновления овариальной функции. Применение женщинами в перименопаузе тамоксифена, подавление овариальной функции (ПОФ) или комбинация ПОФ с тамоксифеном все еще остаются стандартной стратегией адъювантной гормонотерапии.
Ключевые слова
Полный текст
![Доступ закрыт](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
Об авторах
В. Ф Семиглазов
НИИ онкологии им. Н.Н. Петровад.м.н., профессор, член-корр. РАМН Санкт-Петербург
В. В Семиглазов
СПбГМУ им. акад. И.П. Павловад.м.н. Санкт-Петербург
Список литературы
- Семиглазов В.Ф., Семиглазов В.В., Дашян Г.А. Эндокринотерапия раннего рака молочной железы. Руководство. М., 2011. 96 с.
- Семиглазов В.Ф., Семиглазов В.В., Манихас А.Г. Рак молочной железы. Химиотерапия и таргетная терапия. М., 2012. 360 с.
- National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Breast Cancer Res. Treat 2008;2.
- Winer E.P., Hudis C., Burstein H.J., et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status Report 2005. J Clin Oncol 2005;23:619-29.
- Miller W.R. Aromatase inhibitors: mechanism of action and role in the treatment of breast cancer. Semin Oncol 2003;30:3-11.
- Smith I.E., Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 2003; 348:2431-42.
- Smith I.E., Dowsett M., Yap Y.S., et al. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J Clin Oncol 2006;24:2444-47.
- Burstein H.J., Mayer E., Partridge A.H., et al. Inadvertent use of aromatase inhibitors in patients with breast cancer with residual ovarian function: cases and lessons. Clin Breast Cancer 2006;7:158-61.
- Fallowfield L. Quality of life of postmenopausal women in the ATAC trial. J Clin Oncol 2004;22:4261-71.
- Henrich J.B., Hughes J.P., Kaufman S.C., Brody D.J., Curtin L.R. Limitations of follicle-stimulating hormone in assessing menopause status: findings from the National Health and Nutrition Examination Survey (NHANES 1999-2000). Menopause 2006;13:171-77.
- Jakesz R., Jonat W., Gnant M., et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005;366:455-62.
- Baum M., Budzar A.U., Cuzick J., et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131-39.
- Coombes R.C., Hall E., Gibson L.J., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081-92.
- Thurliman B. A comparison of letrozole and tamoxifen in postmenopausal women in early breast cancer. N Engl J Med 2005;353:2747-57.
- Boccardo F., Rubagotti A., Puntoni M., et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian TamoxifenAnastrozole Trial. J Clin Oncol 2005;23:5138-47.
- Goss P.E., Ingle J.N., Martino S., et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97:1262-71.
- Gracia C.R., Sammel M.D., Freeman E.W., et al. Defining menopause status: creation of a new definition to identify the early changes of the menopausal transition. Menopause 2005;12;128-35.
- Smith-DiJulio K., Mitchell E.S., Woods N.F. Concordance of retrospective and prospective reporting of menstrual irregularity by women in the menopausal transition. Climacteric 2005;8:390-97.
- Clemons M., Simmons C. Identifying menopause in breast cancer patients: considerations and implications. Breast Cancer Res Treat 2007;104:115-20.
- Minton S.E., Munster P.N. Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer. Cancer Control 2002;9:466-72.
- Walshe J.M., Denduluri N., Swain S.M. Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol 2006;24:5769-79.
- Klijn J.G., Blamey R.W., Boccardo F., et al. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 2001;19:343-53.
- Celio L., Martinetti A., Ferrari L., et al. Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study. Anticancer Res 1999;19:2261-68.
- Parulekar W.R., Day A.G., Ottaway J.A., et al. Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study-NCIC CTG MA.5. J Clin Oncol 2005;23:6002-08.
- Recchia F., Saggio G., Amiconi G., et al. Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma. Cancer 2006;106:514-23.
- Jannuzzo M.G., Di Salle E., Spinelli R., et al. Estrogen suppression of 8-week treatment with exemestane combined with triptorelin versus triptorelin alone in healthy premenopausal women. J Clin Oncol 2004;22(14S):2041.
- Carlson R. Goserelin plus anastrozole for treatment of premenopausal women with hormone receptor positive recurrent/metastatic breast cancer [Abstract]. Breast Cancer Res Treat 2004;88(1):S237-38.
- Hargis J.B., Nakajima S.T. Resumption of menses with initiation of letrozole after five years of amenorrhea on tamoxifen: caution needed when using tamoxifen followed by aromatase inhibitors. Cancer Invest 2006;24:174-77.
- Duggan C., Marriott K., Edwards R., Cuzick J. Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer. J Clin Oncol 2003;21:3588-93.
- Gradishar W.J. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women. Oncology 2005;691-99.
Дополнительные файлы
![](/img/style/loading.gif)